Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Fangyu Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4191-7355; OpenAlex author ID A5018894451. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 5 papers · 2020: 5 papers · 2021: 6 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper

Papers 23

  1. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. First author DOI 10.2147/cmar.s465098↗
  2. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  3. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
  4. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Co-author DOI 10.1093/bjs/znac375↗
  5. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
  6. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  7. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  8. Targeting hypoxic tumor microenvironment in pancreatic cancer. Co-author DOI 10.1186/s13045-020-01030-w↗
  9. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.709669↗
  10. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.596573↗
  11. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  12. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  13. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Co-author DOI 10.1038/s41388-020-1260-1↗
  14. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  15. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Co-author DOI 10.1186/s12935-020-1147-9↗
  16. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Co-author DOI 10.1186/s12943-020-01169-7↗
  17. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Co-author DOI 10.1002/cam4.2384↗
  18. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1103-2↗
  19. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0777-7↗
  20. Low hENT1 expression indicates poor prognosis in gemcitabine-treated pancreatic cancer patients First author DOI 10.21203/rs.2.17850/v1↗
  21. [The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2019.09.009↗
  22. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Co-author DOI 10.1002/1878-0261.12393↗
  23. Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production. Co-author DOI 10.18632/oncotarget.3878↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 21 shared papers, 2018–2024 · strength 2.52
  2. Gang Yang · 19 shared papers, 2018–2023 · strength 2.17
  3. Lei You · 17 shared papers, 2018–2024 · strength 1.88
  4. Yueze Liu · 14 shared papers, 2019–2024 · strength 1.78
  5. Yupei Zhao · 16 shared papers, 2018–2023 · strength 1.76
  6. Guangyu Chen · 10 shared papers, 2020–2023 · strength 1.29
  7. Wenhao Luo · 9 shared papers, 2019–2024 · strength 1.13
  8. Jiangdong Qiu · 8 shared papers, 2019–2024 · strength 1.09
  9. Jiangdong Qiu · 9 shared papers, 2019–2023 · strength 1.07
  10. Zhe Cao · 9 shared papers, 2019–2023 · strength 0.98
  11. Jinxin Tao · 6 shared papers, 2021–2023 · strength 0.91
  12. Mengyu Feng · 8 shared papers, 2019–2023 · strength 0.86
  13. Jianchun Xiao · 6 shared papers, 2019–2024 · strength 0.80
  14. Guangbing Xiong · 5 shared papers, 2019–2023 · strength 0.56
  15. Dan Su · 3 shared papers, 2022–2023 · strength 0.50
  16. Gang Yang · 3 shared papers, 2019–2024 · strength 0.46
  17. Jinshou Yang · 4 shared papers, 2019–2021 · strength 0.42
  18. Hua Huang · 2 shared papers, 2021–2023 · strength 0.28
  19. Jin Gu · 2 shared papers, 2020–2021 · strength 0.21
  20. Francesca Ricciardiello · 2 shared papers, 2020–2021 · strength 0.21
  21. Ferdinando Chiaradonna · 2 shared papers, 2020–2021 · strength 0.21
  22. Yi‐Cheng Wang · 2 shared papers, 2019 · strength 0.18
  23. Lei Wang · 1 shared paper, 2023 · strength 0.16
  24. Renyi Qin · 1 shared paper, 2023 · strength 0.16
  25. Cheng‐Feng Qin · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.